KUBio BSL-2 Manufacturing solutions
Accelerate your vaccine readiness with modular solutions
Stop waiting, start making viral vectors with KUBio BSL-2 options
The viral vector capacity gap is increasing, leading manufacturers to evaluate critical buy vs build manufacturing strategies. We can help with rapid flexible and comprehensive solutions. Depending on your capacity requirements, select the KUBio BSL-2 modular facility or the KUBio box for viral vectors. Both end-to-end solutions are expandable and include FlexFactory single-use processing lines, integrated Figurate automation, and proven processing support and expertise.
Learn moreAccelerate the production of viral vector-based therapies
The KUBio box for viral vector solution can be on your site in as little as 10 months. This turn-key package is designed specifically for efficiently manufacturing Adeno associated virus and Lenti virus based biotherapeutics. This Biosafety level 2 (BSL-2) environment includes a proprietary FlexFactory viral vector single use work flow that has been designed to deliver flexibility and reduce your risk of contamination. The KUBIO box footprint can also be expanded as you production needs change.
Learn moreAdvance large scale manufacturing in a secure environment
When your production plan calls for a larger scale of manufacturing, the KUBio™ BSL-2 modular facility offers a flexible, expandable solution in as little as 18 months. Realize flexibility and gain confidence with speed and efficiency. KUBio™ BSL-2 facilities include a FlexFactory™ single-use biomanufacturing platform, integrated Figurate™ automation, and processing support. A second complete processing environment can expand your footprint from 2350 m2 to 3850 m2.
Learn how to accelerate your biomanufacturing capacity with KUBio™ box modular environmentsFlexibility with speed and risk mitigation
Capacity expansion decisions typically require investments early in the drug lifecycle when the risks are high. KUBio modular facilities compress facility construction timelines 50% with concurrent module, process equipment, and site work. Capital expenses can be delayed or invested elsewhere until the chance of success is higher.
SEE THE BENEFITS OF KUBIO SOLUTIONSFlexibility with single-use technologies
Viral vector and virus manufacturing look to single-use technologies to enable multi-product production, add efficiencies, and reduce contamination risks. Older technologies used to produce vaccines in eggs are a thing of the past. Unlock the future with an integrated FlexFactory manufacturing line and Cytiva experience and support.
LEARN MORE ABOUT FLEXFACTORY